Travoprost patient responses revealed

Article

A recent study was unable to conclude whether intraocular penetration of travoprost 0.004% was affected by central corneal thickness (CCR), potentially explaining differences in patient response to the drug.

A recent study was unable to conclude whether intraocular penetration of travoprost 0.004% was affected by central corneal thickness (CCR), potentially explaining differences in patient response to the drug.

Dr J.M. Martinez-de-la-Casa et al., Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos, Madrid, Spain, observed 64 patients who were scheduled for cataract surgery without any additional ophthalmologic pathology.

Two hours before surgery a single drop of travoprost 0.004% was administered in the eye due for operation. AL-5848 concentration was determined by extracting a sample of aqueous humour.

They were compared to three patient groups identified by CCT measurements obtained by ultrasound pachymetry. Group 1 had a CCT 574 microns.

The results demonstrated a mean AL-5848 concentration of 3.27±2.03 in group 1, 3.27±2.44 ng/mL in Group II and 2.73±2.15ng/mL in group 3, meaning there were no significant differences between the groups.

The paper, published in the journal Eye can be read here.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.